Navigation Links
Intercept Pharmaceuticals Raises $25 Million Series B Financing
Date:1/25/2010

NEW YORK, Jan. 25 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the completion of a $25 million Preferred Series B financing by its majority shareholder Genextra S.p.A.

Dr. Mark Pruzanski, founder, President and CEO commented, "This financing is recognition of the success we have had advancing our lead compounds INT-747 and INT-777. Genextra's strong backing will enable us to advance our clinical programs while continuing to build our pipeline of novel small molecules targeting FXR, TGR5 and other bile acid receptors."

In conjunction with the financing, Dr. Lorenzo Tallarigo, CEO of Genextra and Intercept director, is assuming the role of Chairman. Dr. Tallarigo stated, "This financing adds substantially to Genextra's investment in Intercept. With two positive Phase II studies last year, the company has made great progress in validating the therapeutic utility of INT-747 and the novel class of compounds it belongs to more broadly."

About Intercept Pharmaceuticals

Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Bile acid signaling through these receptors regulates key aspects of lipid, glucose and overall energy metabolism, while also serving to maintain the functional integrity of the liver, intestine and kidney, organs that are exposed to bile acid flux.

About INT-747 (first-in-cla
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
2. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
3. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
4. Amylin Pharmaceuticals to Webcast Year-End Financial Results
5. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
6. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
7. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
8. Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms
9. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
10. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
11. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Agena Bioscience TM today announced the establishment of a ... financial hub from which many biotech and life science firms ... China . "The Chinese market ... almost sixty MassARRAY ® Systems installed to date. Direct ... to expand our reach and foster a high degree of ...
(Date:9/1/2015)... LOS ANGELES , Sept. 1, 2015 /PRNewswire/ ... biopharmaceutical research and development company specializing in oncology, ... Chairman and Chief Executive Officer, and David ... Investor Relations, will present a corporate overview at ... spotlight the biotechnology and healthcare industries: the FBR ...
(Date:9/1/2015)... In nur zwei Jahren nach dem ... SHL Group schnell weltweit 3.000 Mitarbeiter erreicht. Diese ... dem Markt der injizierbaren Medikamente und ... von SHL wieder. Foto - ... in Design und Herstellung automatischer Injektoren und Pen-Injektoren ...
Breaking Medicine Technology:Agena Bioscience Opens Office in Shanghai, China 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 3CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 4SHL Group erreicht wichtigen Markstein von 3.000 Mitarbeitern 2
... Services Holdings Limited (the "Company" or "Concord Medical") (NYSE: ... of radiotherapy and diagnostic imaging centers in China, today ... CCM Academic Conference in Beijing on December 3 and ... and researchers shared their clinical and academic experience in ...
... /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI), ... Industrial Co, Ltd (Yinfa), the leader in GAP ... People,s Republic of China under the registered Trademark ... project in collaboration with Chengdu Chinese Traditional Medicine ...
Cached Medicine Technology:Concord Medical Completes its Twelfth Annual Academic Conference 2Concord Medical Completes its Twelfth Annual Academic Conference 3China Health Resource Completes Key Research Project - New Proprietary Product Lines 2China Health Resource Completes Key Research Project - New Proprietary Product Lines 3China Health Resource Completes Key Research Project - New Proprietary Product Lines 4
(Date:9/2/2015)... ... September 02, 2015 , ... Based ... GROUP is internationally known as an industry leader specializing in surplus used medical ... selling more than 100,000 pieces of medical equipment every year. Erik Tivin, Chairman ...
(Date:9/2/2015)... ... 2015 , ... “ G-Hold ” was featured on NewsWatch as part of ... consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the review ... a tablet while reducing the likelihood of it dropping. , Tablets like the iPad ...
(Date:9/2/2015)... NC (PRWEB) , ... September 02, 2015 , ... ... IT and business services, has been named to the Inc. 5000 List, an ... has been publishing this list for 34 years, and this achievement puts Canopy ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... reputation for the telling the truth about medicine and health, truths that other ... video blog, where he plans to regularly debunk certain misconceptions surrounding cholesterol, metabolically ...
(Date:9/1/2015)... Miami, FL (PRWEB) , ... September 01, 2015 ... ... Food and Drug Administration (FDA) for the treatment of androgenic alopecia in adults, ... the brand new laser therapy cap, while also demonstrating its safety when used ...
Breaking Medicine News(10 mins):Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:Canopy Partners Named to 2015 Inc. 5000 Fastest Growing Companies List 2Health News:Dr. Michael Rothman, NJ’s Leading Holistic Doctor, Presents a Video Blog that Discusses the Most Confusing and Interesting Current Medical Topics 2Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2
... from around the world met at a conference in ... in obesity. One line of discussion looked at factors ... it might be avoided. , Co-chairs of the conference, ... Research and Dr Jennifer Lovejoy from the University of ...
... directed KH Real Estate to issue a boil water advisory to ... Armstrong County, after samples taken by DEP tested positive for fecal ... received complaints from residents after two customers were hospitalized with intestinal ... for the bacteria. , , ...
... NEW YORK, Nov. 24, 2008 Forest Laboratories, Inc. (NYSE: ... and Trademark Office ("USPTO") has closed prosecution on the merits ... confirmed the validity of all of the previously granted claims. ... Intent to Issue Ex Parte Reexamination Certificate for U.S. Patent ...
... treatment system for advanced radiation therapy, today announced that Rafael (Ralph) ... effective December 1, 2008. Mr. Vaello, who will report to TomoTherapy ... the sales and field marketing group for Philips Healthcare’s Oncology Imaging ... ...
... celebrity trainer Ramona Braganza offers tips to stay trim over the holidays and ... without packing on the pounds. , , ... trimmings: , , , ... before you load your plate for dinner or head out to a holiday ...
... of them currently abstain from alcohol, drugs , , MONDAY, ... Americans over the age of 12 participate in self-help ... 2.3 million who currently abstain from use of these ... Monday by the federal Substance Abuse and Mental Health ...
Cached Medicine News:Health News:Why women should eat less, move more and consider wearing transdermal HRT patches during menopause 2Health News:Pennsylvania DEP Directs Shadyside Water Supply to Issue Boil Water Advisory 2Health News:USPTO Confirms Validity of Bystolic(R) Patent 2Health News: TomoTherapy Names Rafael Vaello Vice President of Global Sales : Former Philips Healthcare executive brings proven sales experience in oncology, imaging industries 2Health News:Tip Sheet: Celebrity Trainer, Ramona Braganza's Tips To Keep Off Those Extra Holiday Pounds 2Health News:5 Million People a Year Use Self-Help Addiction Programs 2
... standard, corrected curve trial lenses are ground with ... Marco refractors and are invaluable in treating low ... other manufacturers contain a disproportionately large number of ... expensive to produce, and fewer lenses in the ...
The LM-990A is the most completely automatic lensemeter ever created. It even measured monocular and binocular PD automatically....
... has made the LM-770 the easiest ... Technicians can be trained to operate ... instruction. The instrument tells the user ... A flashing indicator alerts the user ...
... designed to perform precise and accurate ... one-third the space of traditional examinations. ... refractors, automatic or digital lensmeters and ... EPIC enables the operator to call ...
Medicine Products: